{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:04:52Z","timestamp":1785143092514,"version":"3.55.0"},"reference-count":59,"publisher":"American Chemical Society (ACS)","issue":"11","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UH3DA048386"],"award-info":[{"award-number":["UH3DA048386"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Training in Addiction Neuroscience","award":["T32DA007278"],"award-info":[{"award-number":["T32DA007278"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Opioid-related overdoses have continued to rise in the past decade and have been further exacerbated by polydrug exposure involving the \u03b12 adrenergic receptor agonist xylazine, a veterinary tranquilizer referred to as \u201ctranq\u201d or \u201ctranq dope\u201d. Despite the growing threat of xylazine and other \u03b12 adrenergic receptor agonists, no FDA-approved treatment or prophylaxis exists for xylazine-induced overdose toxicity in humans. To address this unmet need, our team developed and characterized a series of novel xylazine-based haptens and their cognate conjugate vaccines. This study tested their efficacy against xylazine-induced pharmacological effects in rats. Our results demonstrated that active immunization provides protection against xylazine by limiting its entry into the brain and mitigating its pharmacological effects. This study also provides preliminary evidence that a xylazine vaccine can be combined with a fentanyl vaccine through a multivalent formulation strategy to provide protection against drug mixtures of xylazine and synthetic opioids. These findings highlight the potential for immunotherapeutics to prevent toxicity resulting from xylazine and polydrug exposure.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c02529","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:35:26Z","timestamp":1780054526000},"page":"12898-12909","source":"Crossref","is-referenced-by-count":0,"title":["Prophylactic\nActive Immunization Protects against\nXylazine-Induced Pharmacological Effects in Rats"],"prefix":"10.1021","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7402-2491","authenticated-orcid":true,"given":"Caroline M.","family":"Kim","sequence":"first","affiliation":[{"name":"University of Washington , , , ,","place":["Seattle, Washington, United States, 98195"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Robert W.","family":"Seaman","sequence":"additional","affiliation":[{"name":"University of Washington , , , ,","place":["Seattle, Washington, United States, 98195"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Marecki","sequence":"additional","affiliation":[{"name":"University of Washington , , , ,","place":["Seattle, Washington, United States, 98195"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajwana","family":"Jahan","sequence":"additional","affiliation":[{"name":"RTI International , , ,","place":["Research Triangle Park, North Carolina, United States, 27709"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Hannon","sequence":"additional","affiliation":[{"name":"University of Washington , , , ,","place":["Seattle, Washington, United States, 98195"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-0005","authenticated-orcid":true,"given":"Jason","family":"Kang","sequence":"additional","affiliation":[{"name":"University of Washington , , , ,","place":["Seattle, Washington, United States, 98195"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Luengas","sequence":"additional","affiliation":[{"name":"University of Washington , , , ,","place":["Seattle, Washington, United States, 98195"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott P","family":"Runyon","sequence":"additional","affiliation":[{"name":"RTI International , , ,","place":["Research Triangle Park, North Carolina, United States, 27709"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pravetoni","sequence":"additional","affiliation":[{"name":"University of Washington , , , ,","place":["Seattle, Washington, United States, 98195"]},{"name":"University of Washington School of Medicine , , , ,","place":["Seattle, Washington, United States, 98195"]},{"name":"Center for Medication Development for Substance Use Disorder , , ,","place":["Seattle, Washington, United States, 98104"]},{"name":"CounterX Therapeutics, Inc , ,","place":["DE, USA, 98109-1728"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2026072621082276000_cit1","doi-asserted-by":"crossref","unstructured":"Spencer, M.; Garnett, M.; Minin\u0303o, A.\n          Drug Overdose Deaths\nin the United States, 2002\u20132022; National\nCenter for Health Statistics, 2023;","DOI":"10.15620\/cdc:135849"},{"key":"2026072621082276000_cit2","doi-asserted-by":"publisher","first-page":"100364","DOI":"10.1016\/j.dadr.2025.100364","article-title":"Xylazine\nprevalence\nand concentration in the Los Angeles fentanyl market, 2023\u20132025","volume":"16","author":"Friedman","year":"2025","journal-title":"Drug Alcohol Depend. Rep."},{"key":"2026072621082276000_cit3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","article-title":"Xylazine\nintoxication in humans and its importance as an emerging adulterant\nin abused drugs: A comprehensive review of the literature","volume":"240","author":"Ruiz-Colo\u0301n","year":"2014","journal-title":"Forensic Sci. Int."},{"issue":"1","key":"2026072621082276000_cit4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50630","article-title":"Xylazine in Overdose Deaths and Forensic\nDrug Reports in US States, 2019\u20132022","volume":"7","author":"Cano","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026072621082276000_cit6","unstructured":"F A A X P L A N I M P L E M E N T A T I O N R E P O R T Fentanyl.\n          \n          Adulterated Or Associated With Xylazine Implementation Report The\nWhite House Executive Office Of The President Office Of National Drug\nControl Policy; The White House Office of\nNational Drug Control Policy, 2024."},{"issue":"10416","key":"2026072621082276000_cit7","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(23)01686-0","article-title":"The emerging\nfentanyl\u2013xylazine syndemic in the USA: challenges and future\ndirections","volume":"402","author":"Zhu","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"2026072621082276000_cit8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/ajad.70030","article-title":"Rise of illicit\nmedetomidine use: A worrisome trend","volume":"34","author":"Sood","year":"2025","journal-title":"Am. J.\nAddict"},{"issue":"48","key":"2026072621082276000_cit9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.15585\/mmwr.mm7348a2","article-title":"Detection\nof Illegally Manufactured Fentanyls and Carfentanil\nin Drug Overdose Deaths\u2500United States, 2021\u20132024","volume":"73","author":"Tanz","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"2026072621082276000_cit10","doi-asserted-by":"publisher","first-page":"qxae172","DOI":"10.1093\/haschl\/qxae172","article-title":"Public health implications of recent\ndeclines in fatal drug overdoses in New York State and the United\nStates","volume":"2","author":"Holtgrave","year":"2024","journal-title":"Health Affairs Scholar"},{"issue":"3","key":"2026072621082276000_cit11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.17161\/kjm.vol16.20624","article-title":"Xylazine Use in Pregnancy: The Effects\nof the Fentanyl Adulterant\nXylazine on Pregnant Patients and the Developing Fetus","volume":"16","author":"Noonan","year":"2023","journal-title":"Kans J. Med."},{"issue":"11","key":"2026072621082276000_cit12","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1021\/acschemneuro.4c00172","article-title":"Classics\nin Chemical\nNeuroscience: Xylazine","volume":"15","author":"Hoffman","year":"2024","journal-title":"ACS Chem. Neurosci."},{"key":"2026072621082276000_cit13","doi-asserted-by":"publisher","first-page":"100155","DOI":"10.1016\/j.addicn.2024.100155","article-title":"Xylazine is an agonist\nat kappa opioid receptors and exhibits sex-specific responses to opioid\nantagonism","volume":"11","author":"Bedard","year":"2024","journal-title":"Addiction neuroscience"},{"issue":"3","key":"2026072621082276000_cit14","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202500041","article-title":"Xylazine\nas an emerging\nnew psychoactive substance; focuses on both 5-HT7 and \u03ba-opioid\nreceptors\u2019 molecular interactions and isosteric replacement","volume":"358","author":"Floresta","year":"2025","journal-title":"Arch. Pharmazie"},{"key":"2026072621082276000_cit15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-319-13680-6_4","article-title":"The Adrenergic\nSystem in Vascular Smooth Muscle","volume-title":"The Cardiovascular\nAdrenergic System","author":"Docherty","year":"2015"},{"issue":"22","key":"2026072621082276000_cit16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI183354","article-title":"Xylazine\ninduces dopamine release and augments the effects of fentanyl","volume":"134","author":"Trinko","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"2","key":"2026072621082276000_cit17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/29767342231214472","article-title":"Xylazine-Associated\nWounds and Related Health Concerns Among People Who Use Drugs: Reports\nFrom Front-Line Health Workers in 7 US States","volume":"45","author":"Carroll","year":"2024","journal-title":"Subst. Use Addict. J."},{"issue":"2","key":"2026072621082276000_cit18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1053\/bean.2000.0083","article-title":"Alpha2-adrenoceptor\nantagonists","volume":"14","author":"Aantaa","year":"2000","journal-title":"Bailliere\u2019s Best Pract.\nRes., Clin. Anaesthesiol."},{"issue":"6","key":"2026072621082276000_cit19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1017\/S1092852924002189","article-title":"Opioid antagonists:\nClinical utility, pharmacology, safety, and tolerability","volume":"29","author":"McIntyre","year":"2024","journal-title":"CNS Spectr. Cambridge University Press"},{"key":"2026072621082276000_cit20","doi-asserted-by":"publisher","first-page":"1346109","DOI":"10.3389\/fpubh.2024.1346109","article-title":"Fact vs.\nfiction: naloxone in the treatment of opioid-induced respiratory depression\nin the current era of synthetic opioids","volume":"12","author":"Dahan","year":"2024","journal-title":"Front\nPublic Health"},{"issue":"23","key":"2026072621082276000_cit21","doi-asserted-by":"publisher","first-page":"14647","DOI":"10.1021\/acs.jmedchem.0c01042","article-title":"Therapeutic and Prophylactic\nVaccines to Counteract Fentanyl Use Disorders and Toxicity","volume":"63","author":"Robinson","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026072621082276000_cit22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/pharmaceutics16010084","article-title":"Vaccines to Treat Substance\nUse Disorders:\nCurrent Status and Future Directions","volume":"16","author":"Lu","year":"2024","journal-title":"Pharmaceutics"},{"issue":"11","key":"2026072621082276000_cit23","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.3390\/vaccines10111778","article-title":"Immunotherapies for\nthe Treatment of Drug Addiction","volume":"10","author":"Hossain","year":"2022","journal-title":"Vaccines"},{"issue":"3","key":"2026072621082276000_cit24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/13543784.2023.2187286","article-title":"The potential\nrole of\nopioid vaccines and monoclonal antibodies in the opioid overdose crisis","volume":"32","author":"Martinez","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"issue":"23","key":"2026072621082276000_cit25","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1016\/j.vaccine.2022.03.053","article-title":"Pre-clinical\nsafety\nand toxicology profile of a candidate vaccine to treat oxycodone use\ndisorder","volume":"40","author":"Hamid","year":"2022","journal-title":"Vaccine"},{"issue":"2","key":"2026072621082276000_cit26","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1021\/acsptsci.3c00228","article-title":"Multivalent Vaccination\nStrategies Protect against Exposure to Polydrug Opioid and Stimulant\nMixtures in Mice and Rats","volume":"7","author":"Song","year":"2024","journal-title":"ACS Pharmacol. Transl.\nSci."},{"issue":"1","key":"2026072621082276000_cit27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41541-023-00697-9","article-title":"A TLR7\/8 agonist increases\nefficacy of anti-fentanyl vaccines in rodent and porcine models","volume":"8","author":"Crouse","year":"2023","journal-title":"npj Vaccines"},{"key":"2026072621082276000_cit28","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00213-025-06751-9","article-title":"A humanized monoclonal\nantibody attenuates fentanyl self-administration and reverses and\nprevents fentanyl-induced ventilatory depression in rhesus monkeys","volume":"242","author":"Galbo-Thomma","year":"2025","journal-title":"Psychopharmacology"},{"issue":"1","key":"2026072621082276000_cit29","doi-asserted-by":"publisher","first-page":"7700","DOI":"10.1038\/s41467-023-43126-0","article-title":"Investigation of\nmonoclonal antibody CSX-1004 for fentanyl overdose","volume":"14","author":"Bremer","year":"2023","journal-title":"Nat. Commun."},{"issue":"19","key":"2026072621082276000_cit30","doi-asserted-by":"publisher","first-page":"16584","DOI":"10.1021\/acsomega.2c00820","article-title":"Preclinical Efficacy\nand Selectivity of Vaccines Targeting Fentanyl, Alfentanil, Sufentanil,\nand Acetylfentanyl in Rats","volume":"7","author":"Baehr","year":"2022","journal-title":"ACS Omega"},{"issue":"35","key":"2026072621082276000_cit31","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1039\/D4CC00883A","article-title":"Evaluation of a\nhapten conjugate vaccine against the \u201czombie drug\u201d xylazine","volume":"60","author":"Lin","year":"2024","journal-title":"Chem. Commun."},{"key":"2026072621082276000_cit32","doi-asserted-by":"publisher","first-page":"107662","DOI":"10.1016\/j.neuropharm.2019.06.001","article-title":"Development of vaccines to treat opioid use disorders\nand reduce incidence of overdose","volume":"158","author":"Pravetoni","year":"2019","journal-title":"Neuropharmacology"},{"issue":"1","key":"2026072621082276000_cit33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1124\/jpet.111.189506","article-title":"An Oxycodone Conjugate\nVaccine Elicits Drug-Specific\nAntibodies that Reduce Oxycodone Distribution to Brain and Hot-Plate\nAnalgesia","volume":"341","author":"Pravetoni","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"2026072621082276000_cit34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1021\/acsptsci.1c00260","article-title":"Efficacy and Selectivity\nof Monovalent and Bivalent Vaccination Strategies to Protect against\nExposure to Carfentanil, Fentanyl, and Their Mixtures in Rats","volume":"5","author":"Crouse","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"23","key":"2026072621082276000_cit35","doi-asserted-by":"publisher","first-page":"14647","DOI":"10.1021\/acs.jmedchem.0c01042","article-title":"Therapeutic\nand Prophylactic\nVaccines to Counteract Fentanyl Use Disorders and Toxicity","volume":"63","author":"Robinson","year":"2020","journal-title":"J. Med. Chem."},{"key":"2026072621082276000_cit36","doi-asserted-by":"publisher","first-page":"107662","DOI":"10.1016\/j.neuropharm.2019.06.001","article-title":"Development of vaccines to treat\nopioid use disorders\nand reduce incidence of overdose","volume":"158","author":"Pravetoni","year":"2019","journal-title":"Neuropharmacology"},{"issue":"8","key":"2026072621082276000_cit37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/jat\/bkac049","article-title":"Xylazine: Pharmacology\nReview and Prevalence and Drug Combinations in Forensic Toxicology\nCasework","volume":"46","author":"Kacinko","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"2026072621082276000_cit38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.66609","article-title":"Xylazine-Induced Necrotic Skin Ulcers\nin a Fentanyl-Injecting\nIndividual in South Florida, United States: A Case Report","author":"Cervantes","year":"2024","journal-title":"Cureus"},{"issue":"4","key":"2026072621082276000_cit39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.32481\/djph.2017.08.011","article-title":"Medication\nAssisted Treatment for Opioid Use Disorder","volume":"3","author":"McKay","year":"2017","journal-title":"Dela J. Public Health"},{"issue":"1","key":"2026072621082276000_cit40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1176\/appi.prcp.20180006","article-title":"Pharmacological\nand Behavioral Treatment\nof Opioid Use Disorder","volume":"1","author":"Sofuoglu","year":"2019","journal-title":"Psychiatr Res Clin Pract."},{"key":"2026072621082276000_cit41","doi-asserted-by":"publisher","first-page":"120094","DOI":"10.1016\/j.jns.2021.120094","article-title":"Looking\nbeyond the opioid receptor:\nA desperate need for new treatments for opioid use disorder","volume":"432","author":"Lee","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"2026072621082276000_cit42","doi-asserted-by":"publisher","first-page":"108653","DOI":"10.1016\/j.neuropharm.2021.108653","article-title":"Pharmacological mechanisms\nunderlying the efficacy of antibodies generated by a vaccine to treat\noxycodone use disorder","volume":"195","author":"Raleigh","year":"2021","journal-title":"Neuropharmacology"},{"issue":"4","key":"2026072621082276000_cit43","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1176\/appi.ajp.2012.12060793","article-title":"Effect of a Nicotine\nVaccine on Nicotine Binding to \u03b2 2 *-Nicotinic Acetylcholine\nReceptors In Vivo in Human Tobacco Smokers","volume":"170","author":"Esterlis","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"2026072621082276000_cit44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002547","article-title":"A Vaccine against Nicotine\nfor Smoking Cessation: A Randomized Controlled Trial","volume":"3","author":"Cornuz","year":"2008","journal-title":"PLoS One"},{"issue":"9","key":"2026072621082276000_cit45","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/ntr\/ntt003","article-title":"Niccine(R), a Nicotine\nVaccine, for Relapse Prevention: A Phase II, Randomized, Placebo-Controlled,\nMulticenter Clinical Trial","volume":"15","author":"Tonstad","year":"2013","journal-title":"Nicotine Tob. Res."},{"issue":"10","key":"2026072621082276000_cit46","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1001\/archgenpsychiatry.2009.128","article-title":"Cocaine Vaccine for\nthe Treatment of Cocaine Dependence in Methadone-Maintained Patients","volume":"66","author":"Martell","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"2026072621082276000_cit47","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1124\/jpet.120.000124","article-title":"Monoclonal Antibodies\nCounteract Opioid-Induced Behavioral and Toxic Effects in Mice and\nRats","volume":"375","author":"Baehr","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"2026072621082276000_cit48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254247","article-title":"Attenuating nicotine\u2019s\neffects with high affinity human anti-nicotine monoclonal antibodies","volume":"16","author":"Raleigh","year":"2021","journal-title":"PLoS One"},{"key":"2026072621082276000_cit49","doi-asserted-by":"publisher","first-page":"116918","DOI":"10.1016\/j.taap.2024.116918","article-title":"Development\nof fentanyl-specific\nmonoclonal antibody (mAb) to antagonize the pharmacological effects\nof fentanyl","volume":"486","author":"Chen","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"6","key":"2026072621082276000_cit50","doi-asserted-by":"publisher","first-page":"2122507","DOI":"10.1080\/21645515.2022.2122507","article-title":"Advancing\nhumanized monoclonal antibody\nfor counteracting fentanyl toxicity towards clinical development","volume":"18","author":"Hicks","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"2026072621082276000_cit51","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1089\/mab.2014.0098","article-title":"Preparation and Characterization\nof a Monoclonal Antibody Against Morphine","volume":"34","author":"Kashanian","year":"2015","journal-title":"Monoclon\nAntib Immunodiagn Immunother"},{"key":"2026072621082276000_cit52","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.lfs.2017.07.006","article-title":"A mathematical model of a recombinant\nhumanized anti-cocaine monoclonal antibody\u2019s effects on cocaine\npharmacokinetics in mice","volume":"184","author":"Wetzel","year":"2017","journal-title":"Life Sci."},{"issue":"4","key":"2026072621082276000_cit53","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.pbb.2005.04.018","article-title":"Evaluation\nof the anticocaine monoclonal antibody GNC92H2 as an immunotherapy\nfor cocaine overdose","volume":"81","author":"Carrera","year":"2005","journal-title":"Pharmacol., Biochem. Behav."},{"issue":"19","key":"2026072621082276000_cit54","doi-asserted-by":"publisher","first-page":"16584","DOI":"10.1021\/acsomega.2c00820","article-title":"Preclinical Efficacy\nand Selectivity of Vaccines Targeting Fentanyl, Alfentanil, Sufentanil,\nand Acetylfentanyl in Rats","volume":"7","author":"Baehr","year":"2022","journal-title":"ACS Omega"},{"issue":"2","key":"2026072621082276000_cit55","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1037\/pha0000670","article-title":"Xylazine suppresses\nfentanyl consumption during self-administration and induces a unique\nsex-specific withdrawal syndrome that is not altered by naloxone in\nrats","volume":"32","author":"Khatri","year":"2024","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"2026072621082276000_cit56","doi-asserted-by":"publisher","first-page":"100155","DOI":"10.1016\/j.addicn.2024.100155","article-title":"Xylazine is an agonist\nat kappa opioid receptors and exhibits sex-specific responses to opioid\nantagonism","volume":"11","author":"Bedard","year":"2024","journal-title":"Addict. Neurosci."},{"issue":"1","key":"2026072621082276000_cit57","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/imr.12861","article-title":"Factors in B cell competition and\nimmunodominance","volume":"296","author":"Abbott","year":"2020","journal-title":"Immunol. Rev."},{"issue":"2","key":"2026072621082276000_cit58","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.pbb.2009.01.015","article-title":"Immunopharmacotherapy:\nVaccination strategies as a\ntreatment for drug abuse and dependence","volume":"92","author":"Moreno","year":"2009","journal-title":"Pharmacol.,\nBiochem. Behav."},{"issue":"2","key":"2026072621082276000_cit59","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1021\/acsptsci.3c00228","article-title":"Multivalent Vaccination\nStrategies Protect against Exposure to Polydrug Opioid and Stimulant\nMixtures in Mice and Rats","volume":"7","author":"Song","year":"2024","journal-title":"ACS Pharmacol. Transl.\nSci."},{"key":"2026072621082276000_cit60","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1124\/jpet.287.100637","article-title":"The Effect\nof a Multivalent Vaccine\non the Pharmacokinetics of Opioids in a Polydrug Scenario in Rats","volume":"389","author":"Song","year":"2024","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c02529","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/11\/12898\/66272995\/acs.jmedchem.5c02529.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/11\/12898\/66272995\/acs.jmedchem.5c02529.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:18:35Z","timestamp":1785140315000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/11\/12898\/5201003\/Prophylactic-Active-Immunization-Protects-against"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,5,29]]},"published-print":{"date-parts":[[2026,6,11]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02529","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]}}}